Dr. Kimball’s training as a medicinal/synthetic organic chemist is exemplified by proven innovation applied to conceptualization and execution of novel synthetic transformations used to overcome published limitations directed against structurally complex natural products. Notably, this included the development of a novel atroposelective Larock heteroannulation macrocyclization towards the DEF ring system critical to the first total synthesis of the natural products chloropeptin I, complestatin and isocomplestatin.

His expertise includes organic synthesis and determining structure-activity requirements for lead optimization of synthetic small molecules. During his doctoral studies under the supervision of Professor Gunda Geog, Dr. Kimball completed the first multistep total synthesis of the anticancer natural product Tyloindicine H and developed a enantio-specific synthesis to produce an analog library with improved potency. Dr. Kimball’s postdoctoral work at The Scripps Research Institute under the direction of Professor Dale Boger included the total synthesis of the structurally complex chiral Chloropeptin natural product family (anti-HIV properties) and analog library development of FAAH inhibitors (anti-pain properties) with improved potency and receptor selectivity.

While at OssiFi, Dr. Kimball continues to harness this innovation to generate sclerostin inhibitor analogs with improved potency (>800X) with robust selective safety profiles. Additional efforts have also improved formulation, PK parameters, and developed controlled releases for lead compounds.

Return to Our Team here.